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Abstract
Background: High-sensitivity C-reactive protein (hs-CRP) assay is of great clinical importance in predicting risks
associated with coronary heart disease. Existing hs-CRP assays either require complex operation or have low
throughput and cannot be routinely implemented in rural settings due to limited laboratory resources.
Methods: We developed a novel hs-CRP assay capable of simultaneously quantifying over 90 clinical samples by
using quantum dots-labeled immunoassay within a standard 96-well microplate. The specificity of the assay was
enhanced by adopting two monoclonal antibodies (mAbs) that target distinct hs-CRP epitopes, serving as the
coating antibody and the detection antibody, respectively. In the presence of hs-CRP antigen, the fluorescence
intensity of the mAb-Ag-mAb sandwich complex captured on the microplate can be read out using a microplate
reader.
Results: The proposed hs-CRP assay provides a wide analytical range of 0.001-100 mg/L with a detection limit of
0.06 (0.19) μg/L within 1.5 h. The accuracy of the proposed assay has been confirmed for low coefficient of
variations (CVs), 2.27% (intra-assay) and 8.52% (inter-assay), together with recoveries of 96.7-104.2%. Bland-Altman
plots of 104 clinical samples exhibited good consistency among the proposed assay, commercial high-sensitivity
ELISA, and nephelometry, indicating the prospects of the newly developed hs-CRP assay as an alternative to
existing hs-CRP assays.
Conclusion: The developed assay meets the needs of the rapid, sensitive and high-throughput determination of
hs-CRP levels within a short time using minimal resources. In addition, the developed assay can also be used to
detect and quantify other diagnostic biomarkers by immobilizing specific monoclonal antibodies.
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Background
Serum high-sensitivity C-reactive protein (hs-CRP) is of
clinical importance as an independent marker for coron-
ary heart disease, with stratifications corresponding to
low (< 1 mg/L), moderate (1-3 mg/L), and high (> 3
mg/L) levels of cardiovascular risks [1-3] and insulin
resistance [4,5].
Over the last decades, various hs-CRP assays have been
developed, including the enzyme-linked immunosorbent
assay (ELISA) [6,7], immunoturbidimetry [8], time-
resolved immunofluorimetric assay [9], and mass spec-
trometry [10]. Among the assays, mass spectrometry-
based measurements are the most accurate and have
been widely used in proteomics [11]. Immunoturbidime-
try assays and time-resolved immunofluorimetric assays
provide excellent sensitivity (better than 2.8 μg/L) with a
detection time of < 1 h [9]. However, these techniques
require relatively expensive instrumentation, rigid opera-
tional protocols and an inflexible set of reagents.
Although ELISAs are frequently performed in most clini-
cal laboratories due to low cost and simplicity, the
accuracies of traditional ELISAs vary considerably when
t h es a m p l ec o n c e n t r a t i o n sa r el o w e rt h a n1μg/L.
Although high-sensitivity ELISAs (hs-ELISAs) improve
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amplification [12-14], the considerably complicated
operation protocols limit their wide clinical applications
[15]. Fluorescence or chemiluminescence-based techni-
ques are useful alternatives in clinical diagnosis because
of their high sensitivities, allowing them to detect small
amounts of proteins and cytokines [16]. Quantum dots
(QDs) are ideal dyes with excellent fluorescence intensity
and photobleaching resistance ability and have been uti-
lized for the detection of various biological analytes, such
as nucleic acids [17-20], proteins [21], cells [22-24], and
organic molecules [25]. Recently, Zhu et al. established
an hs-CRP assay with QD labeling and immunoaffinity
separation [26]. However, this assay is restricted in large-
scale clinical sample determination due to its complex
operation and stringent reagent requirements. In con-
trast, hs-CRP assays, with the ability to sensitively and
economically analyze 50-100 samples simultaneously,
meet the needs for the rapid and early diagnosis of heart
disease. Unfortunately, no such high-throughput QDs-
based hs-CRP assays have been reported until now.
In this paper, we report a low cost hs-CRP assay cap-
able of analyzing 90 clinical serum samples simulta-
neously. This quantum dot-labeled microplate
immunoassay (QL-MI) combined the features of QD
labeling in microplate format, allowing the fluorescence
intensity to be read out using a microplate reader, which
is available in most clinical laboratories. In a typical QL-
MI assay, two monoclonal antibodies (mAbs) against dis-
tinct epitopes of hs-CRP were applied to enhance the
specificity of the assay. The hs-CRP antigen is captured
by the mAb immobilized on the microplate, then the
QD565 labeled detection antibody is introduced to form
an mAb-Ag-mAb sandwich complex. The induced fluor-
escence intensity (FI) is proportional to the concentration
of serum hs-CRP. In this study, the optimal operation
conditions, including mAb coating concentration and
incubation time, are discussed. Furthermore, two formats
are designed for different clinical applications. A one-
step QL-MI that requires shorter detection time can be
applied for large-scale sample screening. Alternatively, a
two-step QL-MI, which introduces the QD565 and mAb
into the microwells separately, provides improved analy-
tical characteristics and can be implemented in routine
clinical applications. Methodological evaluation of 104
clinical serum samples confirmed that the proposed hs-
CRP assay is highly comparable with existing hs-ELISAs
and nephelometry.
Methods
Materials and reagents
All serum samples were collected from the Southwest
Hospital (China) between May 2009 and Jan 2010.
There were a total of 104 serum samples used in the
study; 68 samples were from healthy individuals under-
going a physical health examination, and 36 samples
were from patients with various inflammation condi-
tions. All participants provided signed informed con-
sents, and the study was approved by the Ethics Boards
of the Third Military Medical University. In this study, 8
mL of peripheral blood was drawn in the morning after
an overnight fast. All of the serum samples were isolated
after centrifugation at 3000 rpm for 15 min and then
immediately stored at -20°C; repeated freeze-thaw cycles
were avoided. Prior to the assay, the frozen samples
were brought to room temperature slowly and gently
mixed. Next, each sample suspension was divided into
four equal portions for analysis by nephelometry, hs-
ELISA, one-step QL-MI, and two-step QL-MI.
High-purity CRP from human serum was obtained
from EMD Biosciences (La Jolla, CA). CRP control serum
was purchased from Beckman Coulter (Brea, CA). The
CRP primary monoclonal antibody (clone 3) was
obtained from Meridian Life Science (Saco, ME). Anti-
CRP (clone 7) was obtained from Santa Cruz (San Fran-
cisco, CA). The Human CRP ELISA Kit was obtained
from Phoenix Pharmaceutical (Burlingame, CA). Purified
human albumin, immunoglobulin G, and hemoglobin
were purchased from Pierce (Rockford, IL). The Qdot
565 ITK Streptavidin Conjugate Kit was obtained from
Invitrogen (Gaithersburg, MD). Phosphate buffered saline
(PBS), bovine serum albumin (BSA), sodium bicarbonate,
and other reagents were obtained from Sigma-Aldrich
(St. Louis, MO). Ultra-pure water (18.2 MΩ·cm) from
Milli-Q (Billerica, MA) was used for the preparation of
all solutions and for the cleaning of substrates. A Synergy
HT Hybrid Multi-Mode Microplate Reader was obtained
from BioTek (Winooski, VT) for fluorescence measure-
ments. UV-transparent, clear-bottom microplates (96-
well) were obtained from Corning (Lowell, MA). A
Microplate Genie mixer from Scientific Industries (Bohe-
mia, NY) was used for reagent mixing.
Coating of 96-well microplates with the primary antibody
Primary CRP mAb coating was achieved through passive
adsorption of the antibody onto the bottom of the micro-
plate, according to the protocol provided by Thermo
Scientific with slight modifications. Briefly, the primary
monoclonal antibody was diluted in a carbonate-bicarbo-
nate buffer (0.2 M sodium carbonate/bicarbonate, pH 9.4),
and 100 μL of appropriately diluted antibody was added
into each well of a 96-well microplate. The plates were
covered with parafilm and incubated for 12 h at 4°C. The
incubation was followed by three washes with a wash buf-
fer (0.1 M PBS, pH 7.2, 0.15 M NaCl, with 0.05% Tween-
20). Next, 300 μL of blocking buffer (wash buffer, pH 7.2,
with 2% BSA) was applied to each well for 2 h to ensure
that all the remaining and available binding surfaces of the
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dried and stored at 4°C until use.
Preparation of the standards and biotinylated anti-CRP
High-purity CRP was diluted in a dilution buffer (PBS,
pH 7.4, with 0.05% Tween-20) from an original concen-
tration of 500 mg/L to concentrations of 0.001, 0.01, 0.1,
1, 10, and 100 mg/L for use as calibration standards. The
preparation of QD-streptavidin conjugates followed the
procedure supplied by Invitrogen. Briefly, QD-streptavi-
din conjugates were centrifuged at 5000 rpm for 3 min
prior to use. Next, 2 μL of the stock supernatant
(approximately 1 μM) was immediately added to 100 μL
of the secondary incubation buffer to produce a 20 nM
QD-streptavidin conjugate solution. The protocol of
anti-CRP biotinylation was supplied by Santa Cruz.
Briefly, 10 mg of biotin was dissolved in 1 mL of anhy-
drous DMSO immediately before use. Biotin was then
mixed with secondary CRP mAb at a concentration ratio
of 80 μg/mg (biotin: mAb). After incubation at room
temperature for 4 h, the unreacted biotin was removed,
and the conjugated antibody was transferred into the sto-
rage buffer by gel filtration or dialysis. The QD-streptavi-
din conjugate or biotinylated CRP mAb was diluted using
a 20% standard diluent buffer prior to use.
Preparation of QD-antibody complex
The QD-mAb complex was prepared according to the
procedure supplied by Invitrogen. Briefly, the monoclonal
antibody and the QD-streptavidin conjugate were mixed
and incubated with slight stirring at 25°C for 2 h to form
the QD-antibody complex. Next, the QD-mAb complex
was concentrated and purified prior to collecting the
absorbance and fluorescence spectra for the effluent. Sam-
ples with an absorbance at 280 nm and no fluorescence at
the emission maximum of the QDs contained excess anti-
bodies. A Bradford assay was performed to calculate the
coupling efficiency by determining the amount of
uncoupled antibody. The conjugated antibody concentra-
tion was determined by subtracting the amount of
uncoupled antibody from the total number of antibodies
used in the assay. The induced concentrations of the QD-
antibody conjugate were determined accordingly.
Measurement procedures
In each well of a 96-well plate, 100 μLo ft h es o l u t i o n
(serum sample or diluted hs-CRP standard) was incu-
bated with the primary mAb that was preabsorbed onto
the well at 25°C for 20 min. Each well was then washed
three times with wash buffer (PBS buffer, pH 7.4, with
0.05% Tween-20) at 2 min per wash. It is essential in
these experiments to place the patient samples and cali-
bration standards on the plates in a manner that mini-
mizes biased readings to obtain reliable results.
Therefore, these measurements were performed in dupli-
cates, and the duplicated samples were placed in different
positions on the plate.
For subsequent hs-CRP detection, two assay formats
were applied (Figure 1): A) a one-step detection with
50 μL of the QD-mAb complex per well at a final concen-
tration of 20 nM (Figure 1A) or B) and a two-step format
that added 50 μLo fb i o t i n y l a t e da n t i - C R Pa n t i b o d yf i r s ti n
each well, followed by three washes and incubation with
50 μL/well of QD-streptavidin (Figure 1B). For both assay
formats, the microplate was washed three times with wash
buffer to remove any unreacted QD-streptavidin complex
or QD-mAb complex prior to fluorescence measurements.
Optimization of reaction conditions
To obtain the optimum conditions for our hs-CRP
assays, various analytical conditions, including the
coated primary monoclonal antibody concentration (1-
10 mg/L) and the concentrations of the QD-conjugated
secondary mAb against hs-CRP (0.1-1 mg L
-1), were
optimized to achieve an ideal regression coefficient for
the standard curve and a high signal-to-noise ratio of
fluorescence intensity.
Methodology comparison and clinical sample detection
The operational characteristics, including the precision,
specificity, analytical sensitivity, and detection limits,
were evaluated to validate the proposed immunoassay.
All 104 clinical samples were analyzed for hs-CRP levels
using one-step QL-MI, two-step QL-MI, hs-ELISA, and
nephelometry (Beckman, Brea CA). Nephelometry and
hs-ELISA assays were performed according to the proto-
cols provided by the suppliers. Bland-Altman plots were
performed with MedCalc (version 11.3) to evaluate the
residuals plots of the proposed and reference methods.
A statistically significant difference between the fluores-
cence intensity induced by various interferents was
tested with t-tests. The results were considered statisti-
cally significant if the P-value was < 0.05. The calibra-
tion curves were plotted using Origin (version 8.1).
Results and discussion
The emergence of hs-CRP as a predicting marker of
future cardiovascular events calls for the rapid, low cost
and high-throughput hs-CRP assays that can determine
slight increases in hs-CRP levels above the normal level
using readily available clinical settings. This study is
aimed to establish such a high-throughput hs-CRP assay
that could be implemented in clinical laboratories
equipped with microplate readers. To generate a high-
throughput model, the widely used 96-well microplate
was adopted as the substrate to immobilize the capture
antibody, a primary mAb against an epitope of hs-CRP
(Figure 1). After the hs-CRP antigen was captured onto
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tope of the hs-CRP was added into the microwell to
form a mAb-Ag-mAb complex. The adoption of two
high-affinity mAbs, targeting distinct epitopes of hs-
CRP, potentially eliminates the false-positive signals
encountered in traditional ELISAs. According to differ-
ences in procedure of introducing the reporter (QD565),
we developed the QL-MI assay in two formats: one-step
QL-MI and two-step QL-MI.
In the one-step assay (Figure 1A), streptavidin-coated
QD565 were preconjugated with the secondary hs-CRP
mAbs with a high coupling efficiency (approximately
95%). To investigate the stability of preconjugated QD-
antibody complex, the storage time of the complex was
studied. No obvious aggregation was observed within
three days when stored at 4°C. However, aggregation can
be observed in the solution when the storage time
increased. Sonication or vortexing resulted in a decreased
limit of detection, indicating that the resulting QD-anti-
body conjugate was not stable for extended storage peri-
ods. We postulate the decreased detection limit is due to
the aggregation of the functionalized QDs after gradually
losing their colloidal stability in the PBS or the fluores-
cence quenching effect by conjugated biomolecules or
the remaining chemicals in the solution [27]. We further
compared the extent by which the FI reduced over time
for CRP detection, QD-streptavidin and QD-mAb stock
solution. The results show that the QD-streptavidin
stock solution has almost no obvious FI decrease within
10 days, and the FI for QD-antibody stock solution
decreases ~16% of its initial value by day 10 (Figure 2A).
However, in case of CRP detection, the corresponding FI
decreased ~20% after 5 days of storage and ~45% after 10
days of QD-mAb storage. These results indicate that in
addition to the aggregation of the QDs, inactivation of
the antibody may also contribute to the decrease in fluor-
escence intensity observed over extend storage time. Two
reasons may attribute to the decrease in fluorescence: (i)
the dissociation of the antibody from the QDs-antibody
conjugate and (ii) improper storage conditions (antibo-
dies should be stored below -20°C or -80°C to avoid the
inactivation of the epitopes, whereas QDs should be kept
at 4°C to avoid decrease in fluorescence). For improved
results, the fluorescence of the Ab-Ag-Ab complex
should be measured immediately, and the longest per-
missible storage time should be shorter than one week in
PBS buffer (pH 7.4). This shortcoming greatly limits the
application of the one-step assay in routine clinical detec-
tion, although it can simplify the procedure and reduce
analysis time.
To avoid the degradation caused by the long-term sto-
rage of the QD-mAb complex, a two-step format was
developed. The biotinylated secondary mAb (detection
antibody) was introduced into the microplate separately
to react with the captured hs-CRP antigen (Figure 1B).
After incubating for 20 min at 37°C, any excess or
Figure 1 Scheme for the two formats of QL-MI. These assays share the same procedure at the first two steps, including monoclonal antibody
coating and antigen introduction. The difference is that A), the QD-mAb conjugate was introduced into the microplate prior to fluorescence
detection in the one-step format while B), the QD-streptavidin was added 20 min later than the biotinylated secondary antibody in two-step
format.
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three rinses with wash buffer. Next, the streptavidin
coated QD565 was added into the microwell followed
by a 10-min incubation to allow the completion of
streptavidin-biotin reaction. Lastly, the fluorescence
intensity was read out using a microplate reader after
washing away any unbound QD-streptavidin. Although
the detection time increased by approximately 20 min
due to the extra incubation and washing steps, the accu-
racy and sensitivity of this format are enhanced by elim-
inating the fluorescence decrease caused by the long-
term storage of the QD-mAb complex.
Optimization of analytical parameters
Various assay parameters (Figure 2B-D) were optimized
for the hs-CRP assay including the concentration of the
captured antibody, the incubation time of the hs-CRP
antigen, and the concentration of the tagged detection
antibody. To simplify the experiment, all our optimiza-
tions were performed using the two-step format. Figure
2B shows that the FI increases proportionally with the
coating antibody concentration for concentrations lower
than 4 mg/L. The FI reaches a maximum at a coating
concentration of 4-6 mg/L and then decreases as the
coating concentration becomes higher than 6 mg/L.
This behavior is primarily attributed to the steric hin-
drance that prevents the formation of the Ag-Ab com-
plex between the mAb coating and the hs-CRP antigen
when the primary mAb is over-coated. Accordingly, the
optimal coating mAb concentration is defined to be 4
mg/L.
Similarly, a time-dependent fluorescence intensity
increase was observed when the serum incubation time
increased from 5 to 30 min (Figure 2C). According to the
combination kinetics between the antigen and the anti-
body, the FI reached a maximum at 20 min when a
dynamic balance was reached between the coating mAb
and the hs-CRP antigen. This balance is confirmed by
the slight increase in fluorescence intensity even with a
longer incubation time. Thus, 20 min was ascertained as
the optimal serum incubation time. Figure 2D reveals
that the optimal detection antibody (biotinylated anti-
CRP) concentration is 0.6 mg/L. To evaluate the optimal
washing procedure, longer incubation times with the
wash buffer and higher Tween-20 concentrations were
tested. The results showed that none of these changes
improved the coefficients of variations (CVs) or elimi-
nated the background measurements. The exception was
that the introduction of Tween-20 in the wash buffer
produced lower background fluorescence signals than the
PBS buffer without Tween-20 (data not shown).
Calibration curves and linearity of analytical results
Figure 3 shows that the proposed hs-CRP assay had a lin-
earity of 0.001-100 mg/L, and no significant difference
was observed in the linearity between the two-step and
one-step formats. In the one-step assay, the regression
equation had a slope of 0.51 (SD, 0.03) and a y-intercept
of 2.93 (SD, 0.04) mg/L with an r
2 value of 0.991. Simi-
larly, in the two-step format, the regression equation had
a slope of 0.49 (SD, 0.02) and a y-intercept of 3.12 (SD,
0.03) mg/L with an r
2 value of 0.994. No significant dif-
ference was observed between the two analytical formats
of QL-MI assay according to the r
2 value. For both analy-
tical formats, the fluorescence intensity could not be
accurately determined at protein concentrations > 100
mg/L due to the lack of curve linearity. To obtain accu-
rate results, serum samples with concentrations higher
than 100 mg/L should be diluted appropriately (10-fold
or more) prior to detection.
Analytical sensitivities and detection limits
The limit of detection (signal-to-noise ratio > 3) was calcu-
lated by measuring the negative control for 20 consecutive
duplicates. The limit of quantification was determined by
serially diluting stock solutions with calibrated dilute
Figure 2 Influence of storage time (A), immobilization
concentration (B), incubation time (C), and detection antibody
concentration (D) on the fluorescence intensity. (A) Fluorescence
intensity after different storage times (1-10 d) for the QD-
streptavidin stock solution only (black line), QD-mAb stock solution
only (red line), and 10 mg/L of the purified CRP standard using QD-
mAb (green line). (B) Various coating concentrations (1-10 mg/L) of
primary anti-CRP monoclonal antibody were employed, and 10 mg/
L of serum hs-CRP was introduced into the detection well to judge
the highest fluorescence intensity. (C) In each determination, the
serum hs-CRP (10 mg/L) was incubated with 4 mg/L of coating
antibody for different time periods (varied from 5-50 min with a 5-
min interval) to determine the optimal reaction time. (D) Various
coating concentrations (0.1-1 mg/L) of capture antibody were
introduced into the microplate (4 mg/L coating antibody) and
reacted with 10 mg/L serum CRP. Error bars indicate the standard
errors of 3 independent experiments.
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tions, and the final diluted concentration, which had a CV
< 20% between replicates, was considered the limit of
quantification. The results showed that the proposed hs-
CRP assay had a limit of detection of 0.06 μg/L and a limit
of quantification of 0.19 μg/L (CV < 8%). Thus, the sensi-
tivity of the assay developed in this experiment is higher
than that of traditional ELISAs or other chemilumines-
cence assays [28] and is comparable to that of hs-ELISAs
[13,29] or previously reported QD-based immunoassays
[26]. For the two-step format assay, a detection limit of
0.21 μg/L and a quantification limit of 0.65 μg/L (CV <
6%) were obtained. The difference in sensitivity between
the two-step and one-step formats is derived from the
slight degradation of the preconjugated QD-mAb complex
with time.
Imprecision and accuracy
Duplicate tests were performed detecting very low (0.03
mg/L), low (0.3 mg/L), medium (3 mg/L), and high con-
centrations (30 mg/L) of CRP in quality control samples.
For every sample, the tests were repeated 20 times
within 1 day for intra-assay analysis and on 20 consecu-
tive days in the same manner (mean of 3 duplicates per
day) for inter-assay analysis. The mean intra-assay and
inter-assay CVs were 2.27% and 9.52% for the one-step
format, respectively, together with 1.75% and 2.17% for
the two-step format, respectively. Our data showed that
the intra-assay results in the two assay formats were
almost identical, whereas the inter-assay variability of
the one-step format was much higher than that of the
two-step format. This is perhaps due to the significant
fluorescence variability of the QD-mAb complex after
long-term storage in the one-step assay, whereas the
QD-streptavidin conjugate can retain highly stable fluor-
escence properties even when stored for a longer period
of time in case of the two-step assay.
Recovery measurements were performed to assess the
overall accuracy of the QD-based assay. The serum sam-
ples were spiked with a known amount of standard hs-
CRP for analysis, and standard hs-CRP concentrations
covered the low, medium, and high-risk patient levels.
Table 1 shows that all of the recovery rates were within
the range of 96.7-104.2%, and no significant differences
in fluorescence intensity were observed between the two
assays (p > 0.01).
Specificities of the QL-MI
Cross-reaction tests were performed by adding 100 μL
of 10 mg/L interferent (albumin, immunoglobulin G,
and hemoglobin) to the detection wells. The results
showed that the fluorescence intensity induced by a spe-
cific Ag-Ab combination (1800 a.u. for 10 mg/L of CRP
serum) was significantly stronger than that (average of
~5.6 a.u. with the range of 2.2-9.8 a.u.) from a nonspeci-
fic interaction (p < 0.05). These weak, nonspecific sig-
nals may be attributed to the background fluorescence
interference caused by the autofluorescence of specific
biomolecules in the serum matrix, which can be elimi-
nated by introducing a reagent blank control consisting
of the serum matrix without any hs-CRP. These results
indicate that the proposed hs-CRP assay provides extre-
mely high specificities, and no significant difference was
observed between the two-step and one-step assays (p <
0.05) (Figure 4).
Clinical sample detection and comparison
For methodology evaluation, 104 clinical serum sam-
ples were analyzed by ELISA, nephelometry, and the
two proposed QL-MI assays. The precision results
obtained from our proposed QL-MI assay are better
than those of many automated hs-CRP methods
[30-32]. We used the Bland-Altman difference plot
analysis to compare the four diagnostic strategies: one-
step QL-MI with hs-ELISA (Figure 5A), two-step QL-
MI with hs-ELISA (Figure 5B), one-step QL-MI with
nephelometry (Figure 5C), and two-step QL-MI with
nephelometry (Figure 5D).
Compared with hs-ELISA, the Bland-Altman difference
plot of the one-step QL-MI showed a mean (SD) differ-
ence (QL-MI minus hs-ELISA) of 25.48 (11.3) μg/L, and
the range for the limits of agreement (d-1.96 S to d +
1.96 S, -201.2 to 150.2 μg/L) was sufficiently narrow. The
two-step QL-MI provided a similar difference of 29.04
(8.5) μg/L, and the agreement limits (-196.9 to 133.8 μg/
L) were sufficiently narrow. Similarly, the one-step QL-
MI provided a difference of 14.71 (8.2) μg/L and a narrow
Figure 3 Calibration curves for hs-CRP detection; 0.001, 0.01, 0.1,
1, 10, and 100 mg/L standard CRP was diluted from CRP stock
solution and reacted with optimal capture antibody (4 mg/L) to
perform this calibration. A) The best fit for the calibration curve is y
= 0.51× + 2.63 with r
2 = 0.991 in the one-step format. The black
solid round is the fluorescence intensities of individual hs-CRP
concentrations and the red straight line is the fitted curve. B) The
best fit for the calibration curve is y = 0.49× + 2.82 with r
2 = 0.994
in the two-step format. The black solid square represents the
fluorescence intensities of individual hs-CRP concentrations with the
red straight line representing the fitted curve. Error bars indicate the
standard errors of 3 independent experiments.
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with nephelometry. The two-step QL-MI provided a
slight difference of 18.27 (7.4) μg/L and a narrow range
of limits (-236.4 to 199.9 μg/L) when compared with
nephelometry. These data suggest good consistency and
clinical equivalence between the proposed hs-CRP assay
and hs-ELISA or nephelometry. Table 2 summarizes a
brief comparison of the advantages and disadvantages
among these four assays. The hs-ELISA assay provides
the best sensitivity among these four assays [12,13],
whereas the nephelometry provides the shortest analyti-
cal time [33]. Compared with these two methods, our
proposed QL-MI assays provide satisfactory analytical
characteristics with a similar sensitivity to hs-ELISA and
a shorter turnaround time.
In addition to its high accuracy and sensitivity, the
QL-MI method allows for high-throughput detection
and automation. For the proposed hs-CRP assay, all of
the operating procedures, including sample introduction,
incubation, vortexing, washing, and fluorescence mea-
surement, can be completed automatically by either a
microplate reader or autoanalyzer. In addition, the
96-well microplate format is capable of simultaneously
determining more than 90 samples in 1.5 h. This analy-
tical time could even be shortened to < 1 h in a one-
step format, making the entire process much faster than
existing mass spectroscopy-based assays. Our future
research is aimed at further improvements in through-
put and standardization of the entire analytical process.
Conclusions
A rapid and sensitive hs-CRP assay for the high-through-
put determination of trace serum hs-CRP was developed
by combining commercially available microplates and
quantum dots labeling. The ability to read out the fluor-
escence signals conveniently using a microplate reader
makes the proposed immunoassay an attractive candidate
for large-scale CRP determination in various clinical
laboratories even without the use of an autoanalyzer.
This assay also provides the prospect for the high-
throughput detection of other biomarkers by coating the
microplate with specific monoclonal antibodies and by
Table 1 Recoveries of QL-MI (n = 20)
Original sample conc. (mg/L) Added conc. (mg/L) Recovered conc. (mg/L) Recovery (%)
one-step format two-step format one-step format two-step format
0.91(0.01)
a 0.89(0.05) 0.87(0.04) 98.92(1.34) 96.73(1.27)
6.32(0.07) 5.01(0.09) 5.21(0.07) 4.89(0.06) 104.21 (2.11) 97.81(2.48)
20.31(0.15) 20.82(0.18) 20.03(0.13) 102.62(2.14) 98.72(3.06)
150.01 (2.25) 154.23 (4.12)
b 146.64(2.13)
b 102.82(3.21) 97.81(2.76)
aNumbers in parentheses denote the standard error of 20 replicated tests
bThese samples were diluted 10-fold before analysis
Figure 4 Cross-reaction of the two assay formats; 100 μLo fa1 0
mg/L solution of albumin (red column), hemoglobin (green
column), and immunoglobulin G (blue column) were introduced
into the coating antibody-immobilized microplate to perform the
cross-reaction. No significant differences were observed between
the fluorescence intensities induced by albumin, hemoglobin, and
immunoglobulin G. However, the fluorescence intensities induced
by nonspecific binding were significantly lower than those induced
by the specific hs-CRP antigen in the one-step assay (p < 0.05) and
in the two-step assay (p < 0.05). Error bars indicate the standard
errors of 3 independent experiments.
Figure 5 Comparison of results for 104 clinical samples from
the proposed QL-MI immunoassay, ELISA, and nephelometry.
Each sample was detected for three duplicates, and the mean of
three results was taken for comparison. Black circles represent the
comparison of 104 clinical samples between the one-step QL-MI
and hs-ELISA (A); two-step QL-MI and hs-ELISA (B); one-step QL-MI
and nephelometry (C); and two-step QL-MI and nephelometry (D).
The black solid line represents the mean difference; dashed lines
represent mean difference ± 1.96 times of the SD of the differences.
Luo et al. Journal of Translational Medicine 2012, 10:24
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Page 7 of 9simply scaling up the 96-well microplate to a 384-well or
higher microplate formats.
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